Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Amy E. Axel
Observed names:
A E Axel,
A. Axel,
Amy Axel,
Amy E Axel,
Axel, A.
Institution:
Immuneering (United States)
Observed institutions:
Nationwide Children's Hospital,
Janssen (Belgium),
University of Florida,
Immuneering (United States),
Janssen Research & Development (United States),
Abigail Wexner Research Institute,
The Ohio State University
show all 7
ORCID:
0009-0000-7039-3469
Observed ORCID:
0009-0000-7039-3469
OpenAlex ID:
A5081535062
Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells
2009
·
N J Sullivan
, A K Sasser
, et al.
·
Oncogene
·
767
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
2016
·
Saad Z. Usmani
, Brendan M. Weiss
, et al.
·
Blood
·
412
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
2016
·
Inger S. Nijhof
, Tineke Casneuf
, et al.
·
Blood
·
403
PDF
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
2017
·
Tineke Casneuf
, Xu Steven Xu
, et al.
·
Blood Advances
·
234
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
2007
·
A. Kate Sasser
, Nicholas J. Sullivan
, et al.
·
The FASEB Journal
·
227
Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
2021
·
Christie P. M. Verkleij
, Marloes E. C. Broekmans
, et al.
·
Blood Advances
·
191
PDF
Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus
2018
·
Suzanne Cole
, Alice Walsh
, et al.
·
Arthritis Research & Therapy
·
133
PDF
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
2016
·
Christopher McCudden
, Amy E. Axel
, et al.
·
Clinical Chemistry and Laboratory Medicine (CCLM)
·
129
PDF
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab
2020
·
Tineke Casneuf
, Homer C. Adams
, et al.
·
Leukemia
·
126
PDF
Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments
2007
·
A. Kate Sasser
, Bethany L. Mundy
, et al.
·
Cancer Letters
·
121
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
2020
·
Kristine A. Frerichs
, Marloes E.C. Broekmans
, et al.
·
Clinical Cancer Research
·
98
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
2016
·
Niels W.C.J. van de Donk
, Henny G. Otten
, et al.
·
Clinical Chemistry and Laboratory Medicine (CCLM)
·
87
PDF
Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening
2012
·
Eberhard Krausz
, Ronald de Hoogt
, et al.
·
SLAS DISCOVERY
·
68
PDF
Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma:rs1800795(Promoter) andrs8192284(Receptor)
2009
·
Joanne P. Lagmay
, Wendy B. London
, et al.
·
Clinical Cancer Research
·
46
PDF
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
2016
·
Christopher Chiu
, Tineke Casneuf
, et al.
·
Blood
·
43
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer
2016
·
Kate Sasser
, Tineke Casneuf
, et al.
·
Breast Cancer Targets and Therapy
·
37
PDF
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
2015
·
Saad Usmani
, Brendan Weiss
, et al.
·
Blood
·
29
Assessing clinical response in multiple myeloma (MM) patients treated with monoclonal antibodies (mAbs): Validation of a daratumumab IFE reflex assay (DIRA) to distinguish malignant M-protein from therapeutic antibody.
2015
·
Christopher McCudden
, Amy Axel
, et al.
·
Journal of Clinical Oncology
·
22
Abstract 2563: Development of clinical assay to mitigate daratumumab, an IgG1κ monoclonal antibody, interference with serum immunofixation (IFE) and clinical assessment of M-protein response in multiple myeloma
2014
·
Amy E. Axel
, Christopher R. McCudden
, et al.
·
Cancer Research
·
22
Overcoming the Interference of Daratumumab with Immunofixation Electrophoresis (IFE) Using an Industry-Developed Dira Test : Hydrashift 2/4 Daratumumab
2016
·
Helene Caillon
, Alix Irimia
, et al.
·
Blood
·
16
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer (NK) Cells with a Distinct Phenotype and Expansion of Effector Memory T-Cells in Pollux, a Phase 3 Randomized Study
2017
·
Niels WCJ van de Donk
, Homer Adams
, et al.
·
Blood
·
14
Pharmacodynamic Relationship Between Natural Killer Cells and Daratumumab Exposure in Relapsed/refractory Multiple Myeloma
2016
·
Casneuf, T.
, Xu, X. S.
, et al.
·
Pure Amsterdam UMC
·
9
Effects of Ibrutinib on Rituximab and GA-101 Induced Antibody-Dependent Cell Cytotoxicity (ADCC) in Lymphoma Cells in Vitro
2014
·
Cuc Davis
, Emily Stepanchick
, et al.
·
Blood
·
9
Preclinical Evaluation of CSL362/JNJ-56022473 in Combination with Decitabine or Azacitidine in in Vitro Assays
2015
·
Khaja Syed
, Christine Pietsch
, et al.
·
Blood
·
7
Preclinical evaluation of the new GPRC5DxCD3 (JNJ-7564) bispecific antibody for the treatment of multiple myeloma
2019
·
Christie Verkleij
, Marloes Broekmans
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
6
Show more works
View as search
Works count:
65
Citation count:
3,269
H-index:
19
I10-index:
21
Year
Topic
Type
